MindMed (NASDAQ:MNMD),which recently received a letter on behalf of one of its shareholders calling for a new business strategy and offering a solution, reported its earnings for the quarter ended June 30, 2022. And the next day, it announced theappointment of two independent directorsto its board.
First, aquick financial report:
Total cash balanceof $105.7 million, expected to be sufficient for the operating requirements beyond key development milestones until 2024.
Net cash usedin operating activities was $28.0 million within six months, compared to $21.2 million for the same period in 2021.
R&D expenses were $9.3 million within three months, compared to...
Login or create a forever free account to read this news
Sign up/Log in